Zhenchuan Song

Prof. Dr. Zhenchuan Song

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2018 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
LYLiu Yang
Liu Yang
YTYanhua Tian
Yanhua Tian
WLWei Sun Leong
Wei Sun Leong
HSHeng Song
Heng Song
WYWei Yang
Wei Yang
ZSZhenchuan Song
Zhenchuan Song
Drug resistance of paclitaxel (TAX), the first-line chemotherapy drug for breast cancer, was reported to develop in 90% of patients with breast cancer, especially metastatic breast cancer. Investigating the mechanism of TAX resistance of breast cancer cells and developing the strategy improving its therapeutic efficiency are crucial to breast cancer cure. We here report an elegant nanoparticle (NP)-based technique that realizes efficient breast cancer treatment of TAX. Using lentiviral vector-mediated gene knockdown, we first demonstrated that TAX therapeutic efficiency was closely correlated with metadherin (MTDH) gene expression in breast cancer cell lines. This finding was also supported by efficacy of TAX treatment in breast cancer patients from our clinical studies. Specifically, TAX treatment became more effective when MTDH expression was decreased in MCF-7 cancer cells by the blocking nuclear factor-kappa B (NF-κB) pathway. Based on these findings, we subsequently synthesized a polymeric NP that could co-deliver MTDH-small interfering RNA (MTDH–siRNA) and TAX into the breast cancer tumors in tumor-bearing mice. The NPs were composed of a cationic copolymer, which wrapped TAX in the inside and adsorbed the negatively charged siRNA on their surface with high drug-loading efficiency and good stability. NP-based co-delivery approach can effectively knock down the MTDH gene both in vitro and in vivo, which dramatically inhibits breast tumor growth, achieving effective TAX chemotherapy treatment without overt side effects. This study provides a potential therapeutic strategy for the treatment of a wide range of solid tumors highly expressing MTDH.

1 January 2017 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
NYNan Yao
Nan Yao
ZSZhenchuan Song
Zhenchuan Song
XWXinle Wang
Xinle Wang
SYShan Yang
Shan Yang
HSHeng Song
Heng Song
Yao N, et al. J Breast Cancer. 2017 Jun;20(2):160-169. https://doi.org/10.4048/jbc.2017.20.2.160

8 March 2019 in Oncology Research and Treatment
Verified
Journal Article
Closed access
PDF file
XWXue Wang
Xue Wang
THTian-Li Hui
Tian-Li Hui
MWMei-Qi Wang
Mei-Qi Wang
HLHuan Liu
Huan Liu
RLRuo-Yang Li
Ruo-Yang Li
ZSZhenchuan Song
Zhenchuan Song
Background: The aim of this study was to investigate the association between body mass index (BMI) and prognosis of Chinese women with breast cancer. Patients and Methods: 3,380 primary breast cancer patients who underwent surgery from 2010 to 2012 were selected and classified as low BMI group (BMI < 25.0) and high BMI group (BMI ≥ 25.0). The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3,178 patients (median follow-up of 58 months). Cox regression analysis was used to evaluate the effect of BMI on DFS and OS. Results: The high BMI group showed more aggressive pathological features. BMI was negatively associated with OS (hazard ratio (HR) 1.33, 95% confidence interval (CI) 1.06–1.66; p = 0.012) but not DFS (HR 1.15, 95% CI 0.94–1.40; p = 0.17). Furthermore, when stratified by age, BMI was significantly and negatively associated with OS (HR 1.43, 95% CI 1.05–1.95; p = 0.025) in patients above 50 years of age, but this effect was not detected in younger patients. Conclusion: BMI was an independent prognostic factor of OS in Chinese women with breast cancer, and age might be a mitigating factor. Among patients above 50 years of age, those with a high BMI were at greater risk of poor prognosis compared to individuals with a low BMI.

4 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LLLei Liu
Lei Liu
ZLZhanlun Liu
Zhanlun Liu
JWJianxin Wang
Jianxin Wang
MCMeng Cheng
Meng Cheng
YXYanli Xie
Yanli Xie
YZYanshou Zhang
Yanshou Zhang
Totally implantable venous access devices (TIVADs) have been widely used for many years in the management of patients suffering from cancer. Thrombotic occlusion is the most common functional complication in the off-treatment period. This study aims to investigate the incidence of and risk factors for TIVADs-related thrombotic occlusion in patients with breast cancer. The clinical data of 1586 eligible patients with breast cancer with TIVADs at the Fourth Affiliated Hospital of Hebei Medical University from 1 January 2019 to 31 August 2021 were analysed. Thrombotic occlusion was confirmed by angiography with signs of partial or total occlusion. Thrombotic occlusion occurred in 96 (6.1%) cases. Multivariable logistic regression analysis showed that the insertion site of the catheter (P = 0.004), size of the catheter (P < 0.001), and indwelling time (P < 0.001) were significant factors for thrombotic occlusion. Insertion in the right internal jugular vein, smaller catheter size and shorter indwelling time can lower the incidence of thrombotic occlusion in breast cancer patients with TIVADs in the off-treatment period.

1 December 2017 in Medicine
Verified
Journal Article
Open access
PDF file
MCMeng Cheng
Meng Cheng
CGCuizhi Geng
Cuizhi Geng
TTTiantian Tang
Tiantian Tang
ZSZhenchuan Song
Zhenchuan Song
Mucoepidermoid carcinoma (MEC) of the breast is a rare entity comprising specific morphological and immunohistochemical features, and has been previously only reported in 33 cases. Four cases of MEC of the breast are reported in this study. All patients were women with ages ranging from 39 to 66 years. The lesions consisted of neoplastic solid nests and cystic spaces sometimes filled with mucoid material. At high power, the tumors were composed of various proportions of basaloid, intermediate, epidermoid, and mucinous cells in different cases. All cases were classified as low-grade MEC of the breast. Tumor cells exhibited low levels of hormonal receptor expression in two cases (cases 1 and 3), and immunonegativity in one case (case 2). On the contrary, estrogen receptors (ER) were positively expressed in 60% of tumor cells in case 4. Tumor cells did not express human epidermal growth factor receptor 2 (HER-2)/neu protein in all the cases. Modified radical mastectomy (Auchincloss) was performed in the first two cases, while the remaining two patients underwent mastectomy plus sentinel lymph node biopsy. All patients were alive and well without evidence of recurrent disease after a period ranging from 4 months to 156 months. MEC of the breast is a rare primary carcinoma that is difficult to diagnose. Multiple tissue blocks are necessary before obtaining all cell types. Special stains for mucin and electron microscopy would be helpful in suspected cases. Hormonal factors might have an impact on the biological behavior of tumors, but further studies are needed to draw conclusions.

12 October 2017 in Oncology Reports
Verified
Journal Article
Open access
PDF file
LYLiu Yang
Liu Yang
ZSZhenchuan Song
Zhenchuan Song
XWXinle Wang
Xinle Wang
WYWei Yang
Wei Yang
MWMeiqi Wang
Meiqi Wang
HLHuan Liu
Huan Liu
Breast cancer is considered as the most common malignant disease in women. Huaier extract, a type of traditional Chinese medicine, has been found to have antitumor activity. In the present study, we aimed to investigate whether the combined treatments of paclitaxel and Huaier extract may improve treatment efficacy in breast cancer cells. Human breast cancer cell lines MCF-7 and MDA-MB-231 were used to evaluate the antitumor efficacy of Huaier extract and paclitaxel both in vitro and in vivo. Using proliferation assays and flow cytometry, we found that both Huaier extract and paclitaxel decreased cell viability and induced cell apoptosis in a time- and dose-dependent manner. The combined treatments were more effective than monotherapy. Huaier extract induced cycle arrest in the G0/G1 phase, and paclitaxel arrested the cell cycle in the G2/M phase. Furthermore, the results of real-time PCR and western blotting revealed that Huaier extract decreased p65 and c-Met expression and increased IκBα expression, while paclitaxel increased p65 expression and reduced IκBα and c-Met expression. Consistent with the in vitro results, both Huaier extract and paclitaxel exerted a significant inhibitory effect on xenografted tumor growth, and the combined therapies revealed the most marked inhibitory effect. Collectively, our results indicated that Huaier extract increased the antitumor effect of paclitaxel therapy in breast cancer cells. The molecular mechanisms may be involved in the inhibition of the NF-κB pathway and c-Met expression.